The global demand for the global drug-integrated polymer fiber market was valued at USD 57 million in 2018, and is expected to generate revenue of USD 90.3 million by the end of 2025, with an annual average growth of 6% between 2021 and 2027.
North America dominated the drug-integrated polymer fiber market, particularly due to the prevalence of obesity and osteoarthritis patients, along with high spending on healthcare facilities in the United States. Currently, TissueGen Inc. and Micro Engineering Solutions Inc. are two major players in the drug-integrated polymer fiber business, but companies operating in the field of biodegradable bone graft polymers are expected to enter the market soon.
A full report of Drug Integrated Polymer Fibers Market available at https://www.orionmarketreports.com/drug-integrated-polymer-fibers-market/10477/
Drug Integrated Polymer Fibers Market: Segmentation
By Order Type
• Polylactic Acid
• Polydioxanone
• Polycaprolactone
By Application
• Drug Delivery
• Orthopaedic Sutures
• Vascular Stents
• Vascular Grafts
• Dermal Wound Healing
Key Companies
• TissueGen
• Micro Engineering Solutions
• Integrated Polymer Solutions
(This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.)
